|Bid||4.4100 x 2900|
|Ask||4.5000 x 2900|
|Day's Range||4.3900 - 4.5500|
|52 Week Range||4.2900 - 6.8800|
|Beta (3Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 5, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.10|
Cerus Corporation announced today its schedule of key events and presentations at the 2019 AABB Annual Meeting which is taking place in San Antonio, Texas on October 19th through October 22nd.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Cerus Corporation applauds the publication of the FDA final guidance document titled Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Guidance for Industry.
Cerus Corporation today announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer will present and provide a corporate update at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019 at 3:00 p.m.
A look at the shareholders of Cerus Corporation (NASDAQ:CERS) can tell us which group is most powerful. Institutions...
Cerus (CERS) delivered earnings and revenue surprises of -8.33% and 5.50%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While small-cap stocks, such as Cerus Corporation (NASDAQ:CERS) with its market cap of US$744m, are popular for their...
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
Cerus Corporation announced today that multiple abstracts featuring the INTERCEPT Blood System pathogen reduction technology, including four oral presentations, will be included in the scientific program at the 29th regional congress of International Society of Blood Transfusion .
Anyone researching Cerus Corporation (NASDAQ:CERS) might want to consider the historical volatility of the share...
Cerus Corporation (CERS) announced today a new corporate branding campaign building upon the Company’s leadership position in helping to safeguard the world’s blood supply and the planned relocation of its corporate offices to a new facility in Concord California. The new corporate brand reflects Cerus’ increasingly important role in helping blood centers globally to proactively protect the blood supply against the threat of known and emerging infectious diseases. The Company aims to be the global leader in pathogen reduction technologies and a trusted partner of blood centers and hospitals.
Cerus Corporation (CERS) today announced that the FDA has issued a final guidance document recommending protocols for reducing the risk of transfusion transmitted Babesiosis. In 15 Babesiosis endemic states, treating donated blood components with the INTERCEPT Blood System is a recognized alternative to year-round Babesia testing using a DNA-based test. “We are pleased that treating donated blood components with a pathogen-reduction technology such as INTERCEPT was selected as one of the two options recognized by the FDA to reduce the risk of transfusion transmitted Babesiosis,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
Cerus (CERS) delivered earnings and revenue surprises of -16.67% and 11.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Concord, California-based company said it had a loss of 14 cents. The biomedical products company posted revenue of $17.5 million in the period. Cerus expects full-year revenue ...